Swiss pharma giant Roche might be seeing competition start to erode sales of its big-selling cancer drugs, but sales of another of its products are heading in the opposite direction. 8 May 2019
At the annual meeting of the American Academy of Neurology (AAN), Switzerland’s Novartis (NOVN: VX) has presented a new analysis of the Phase III EXPAND study of Mayzent (siponimod). 8 May 2019
Lundbeck today announced first-quarter 2019 financials, showing that revenue reached 4,234 million Danish kroner ($634.8 million), representing a decline of 8% (6% in local currencies) compared to the same period last year. 8 May 2019
US biotech Cytokinetics has announced that its Phase II FORTITUDE-ALS trial of reldesemtiv in amyotrophic lateral sclerosis (ALS) failed to meet its primary endpoint. 7 May 2019
In a third collaboration with a pharma major within less than a year, US privately-held biotech Skyhawk Therapeutics has entered into a strategic collaboration with Japanese giant Takeda Pharmaceutical. 7 May 2019
Danish CNS specialist Lundbeck on Monday announced the signing of a definitive agreement into acquire La Jolla, USA-based Abide Therapeutics. 7 May 2019
US pharma major Eli Lilly has released positive results from pooled subgroup analyses of efficacy data from the Phase III EVOLVE-1 and EVOLVE-2 studies. 7 May 2019
The US Food and Drug Administration on Friday published the draft guidance for industry, Attention Deficit Hyperactivity Disorder: Developing Stimulant Drugs for Treatment, to provide general recommendations to companies developing stimulant drugs for treatment of ADHD in pediatric and adult patients. 4 May 2019
An Evidence Report assessing the comparative clinical effectiveness and value of Swiss pharma giant Novartis’ Mayzent (siponimod) for the treatment of secondary progressive multiple sclerosis (SPMS) was released on Thursday by the USA’s Institute for Clinical and Economic Review (ICER). 3 May 2019
East Coast, USA-based biotech BioXcel Therapeutics says it has finalized formulation development for its candidate BXCL501, with the aim of supporting a Phase III trial later in the year. 3 May 2019
Israeli generics giant Teva Pharmaceutical Industries today posted first-quarter 2019 financials, showing declines but these were slightly less than observers had expected. 2 May 2019
The UK’s healthcare authority has published a new guideline for healthcare professionals, indicating the symptoms and signs which should prompt a referral for further neurological assessment. 2 May 2019
Japanese drug major Eisai says that its US subsidiary has bought out Purdue Pharma's rights in the worldwide collaboration for the evelopment and commercialization of investigational dual orexin receptor antagonist lemborexant. 1 May 2019
The US Food and Drug Administration has issued a new Boxed Warning for certain common prescription insomnia medicines, due to “several reports of rare, but serious injuries and deaths.” 1 May 2019
Back on full form since its move to Amsterdam, the European Medicines Agency’s Committee for Medicinal Products for Human Use committee (CHMP) recommended nine novel medicines for approval at its April 2019 meeting. 27 April 2019
US Health Secretary Alex Azar has outlined progress combating the ongoing opioid crisis, with an update one year on from a pledge from the US President to reduce unnecessary opioid prescriptions, expand treatment, and boost access to naloxone. 25 April 2019
Shares in Biogen dropped almost 2% on Wednesday morning, despite an upbeat financial results statement which indicated higher-than-expected revenue and earnings. 24 April 2019
Alder BioPharmaceuticals has submitted for US approval for eptinezumab, an investigational monoclonal antibody, and the firm’s lead candidate. 24 April 2019
Shares in Swiss pharma giant Novartis shot up by 2.5% in Wednesday morning’s trading after the company presented its first quarter financial results. 24 April 2019
Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Neimann-Pick disease, type C (NPC). 20 September 2024
US neuroscience company BioXcel Therapeutics has announced a new clinical prioritization and an update on its late-stage development programs for the treatment of agitation with BXCL501. 20 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US clinical stage CNS drug developer Athira Pharma is taking decisive action following the company’s announcement of disappointing data from the Phase II/III LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD). 18 September 2024
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
The cost of prescribed dependency-forming medicines has decreased by £410 million ($539.6 million) since 2015/16, according to newly released data from the UK’s National Health Service (NHS). 6 September 2024
Shares in US biopharma Axsome Therapeutics, a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, closed 7% higher on Wednesday. 5 September 2024
Mid-Atlantic BioTherapeutics (MABT) has announced a collaboration with Accelero Biostructures to identify novel inhibitors of USP30, a protein linked to neurological disorders and other conditions. 5 September 2024
Praxis Precision Medicines shared positive top-line results for its Phase II, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. 4 September 2024